Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET
Company Participants
Dale A. Sander – CFO, Chief Corporate Development Officer & Treasurer
Laura E. Niklason – Founder, President, CEO & Director
William John Scheessele – Chief Commercial Officer
Conference Call Participants
Bruce David Jackson – The Benchmark Company, LLC, Research Division
Joshua Thomas Jennings – TD Cowen, Research Division
Ryan Benjamin Zimmerman – BTIG, LLC, Research Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
Thomas Johnson – Lifesci Advisors, LLC
Operator
Good morning, ladies and gentlemen, and welcome to the Humacyte Second Quarter 2025 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to Tom Johnson with Lifesci Advisors. Please go ahead.
Thomas Johnson
Thank you, operator. Before we proceed with the call, I’d like to remind everyone that certain statements during this call are forward- looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.
The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which after the filing may be accessed from the Investor page of the Humacyte website.
Joining me today on today’s call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer; Dale Sander, Chief Financial Officer and Chief Corporate
